Market Overview

Allergan Considering All Strategic Options 'With A Sense Of Urgency'

Allergan Considering All Strategic Options 'With A Sense Of Urgency'
Related AGN
Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates
Jim Cramer Weighs In On Allergan, Procter & Gamble And More
Entasis Therapeutics files for $86.25M initial public offering (Seeking Alpha)

Allergan plc Ordinary Shares (NYSE: AGN) continued its two-week, 16-percent rebound Wednesday, and RBC Capital Markets anticipates 28 percent of additional upside.

The Rating

Analyst Randall Stanicky maintained a Buy on Allergan with a $213 price target.

The Thesis

Management’s afternoon investor conference convinced Stanicky that Allergan is urgently evaluating all strategic options with an expressed “bias for action." (See the analyst's track record here.)

“In our view, it is going to keep asset sale/break-up debate in the stock and specifically around how much value can be created,” Stanicky said. “We continue (and as we have highlighted since October) to see meaningful value that can be unlocked with ‘Growth-co’ alone worth about $200 per share.”

Allergan continues to expand its toxins portfolio, and it considers its leading Botox treatment insulated from competition by the hurdles limiting biosimilars, including a lack of regulatory pathways and interchangeability, according to RBC Capital Markets.

“It won't eliminate concern, but it helps,” Stanicky said. 

Also of note: Allergan has accelerated its $2-billion buyback program and expects to complete it in April, well ahead of the year-end target.

Price Action

Allergan added a couple dollars on RBC’s reaffirmed confidence to close up 2.4 percent Wednesday. At the time of publication, it was set to open up marginally Thursday.

Related Links:

Goldman Sachs Sees 100% Upside In This Biopharma Company

Cantor Fitzgerald Names 8 Upcoming Biotech Catalysts

Photo courtesy of Allergan. 

Latest Ratings for AGN

Jun 2018Bank of AmericaMaintainsBuyBuy
Jun 2018MizuhoMaintainsNeutralNeutral
May 2018Credit SuisseMaintainsOutperformOutperform

View More Analyst Ratings for AGN
View the Latest Analyst Ratings

Posted-In: Randall Stanicky RBC CapitalAnalyst Color Health Care Price Target Reiteration Analyst Ratings General Best of Benzinga


Related Articles (AGN)

View Comments and Join the Discussion!

MLP ETFs Endure Rough First Quarter, Global X Says New Tax Rule Could Help

KeyBanc Upgrades Akamai Technologies As Focus Turns To Margin Expansion